Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,880.80
(
0.58%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
95.26
(
-0.74%
)
Bitcoin
67,749.36
(
-5.07%
)
News Focus
News Focus

Replies to post #1829 on Revance Therapeutics Inc (RVNC)

Replies to #1829 on Revance Therapeutics Inc (RVNC)
icon url

DewDiligence

03/16/21 11:59 AM

#1830 RE: valiano #1829

2021 dermal-filler sales will make a dent in the cash burn, but they won’t offset it entirely. RVNC’s guidance for 2021 cash operating expenses is $270-285M (#msg-162045598). I will be happy if 2021 dermal-filler sales reach $100M.